Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Tax Provisions: 2012-2024

Historic Tax Provisions for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to -$3.7 million.

  • Ani Pharmaceuticals' Tax Provisions rose 198.20% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 743.43%. This contributed to the annual value of -$3.7 million for FY2024, which is 437.60% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Tax Provisions stood at -$3.7 million for FY2024, which was down 437.60% from $1.1 million recorded in FY2023.
  • Ani Pharmaceuticals' Tax Provisions' 5-year high stood at $9.8 million during FY2020, with a 5-year trough of -$14.8 million in FY2022.
  • Its 3-year average for Tax Provisions is -$5.8 million, with a median of -$3.7 million in 2024.
  • Its Tax Provisions has fluctuated over the past 5 years, first surged by 107.40% in 2023, then plummeted by 437.60% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Tax Provisions (Yearly) stood at $9.8 million in 2020, then tumbled by 237.42% to -$13.5 million in 2021, then decreased by 9.77% to -$14.8 million in 2022, then spiked by 107.40% to $1.1 million in 2023, then tumbled by 437.60% to -$3.7 million in 2024.